Friday, October 31, 2014
BGI Tech Solutions, a subsidiary of BGI, a genomics research organization, and South Texas Accelerated Research Therapeutics (START), are collaborating on the San Antonio 1000 Cancer Genome Project (SA1kCGP), a cancer genome study designed to link genetic alterations that underlie different cancers to detailed clinical outcomes. Such findings could enable scientists to pursue the development of targeted, personalized cancer treatments. All data generated from SA1kCGP will be made available publicly and freely to researchers and others worldwide.
Merck and BGI have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies. Under the agreement scientists from Merck and BGI will work closely together to identify and characterize biomarkers with an emphasis on drug discovery, drug development and diagnostics applications across a wide range of therapeutic areas.